132
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Further optimisation of a macromolecular ocular irritation test (OptiSafeTM)

, , &
Pages 38-48 | Received 05 Oct 2021, Accepted 27 Nov 2022, Published online: 28 Jan 2023
 

Abstract

Purpose

OptiSafeTM (OS) is a shelf stable, nonanimal test for ocular irritation. A recent database search found that half of the OS false positive (FP) materials were associated with reactive oxygen chemistries but were not eye irritants in vivo (based on historical rabbit studies by other groups). We hypothesized that naturally occurring tear antioxidants protect the eye from reactive chemistries in vivo and that specific tear chemistries might help explain why some materials are FP for nonanimal tests but are reported as nonirritants in the live animal. To test this hypothesis, a prior study evaluated tear antioxidants and found that the tear antioxidant ascorbic acid, added at human physiological tear levels to the OS test, specifically reduced the measured values for these FPs but did not reduce the true-positive rate. Based on these findings, the OS test method was further optimized. The purpose of the current study was to comprehensively evaluate the performance of the further optimized test method for detection of ocular irritants.

Materials and methods

The OS test measures chemically induced damage to macromolecules and relates these measured values to ocular irritancy. To improve the performance of OS, we made updates to the material to be tested physiochemical handling procedures, prediction model, and test method to include tear-level concentrations of ascorbic acid. We then retested the 78 chemicals from the prior OS-coded validation study in triplicate and compared the accuracy of the ‘nonirritant versus irritant’ prediction for the further optimized method with the prior results.

Results

We report that for the detection of ‘nonirritant’ versus ‘irritant’ (GHS NC versus categories 2B/A and 1) test substances, the further optimized OS test with ascorbic acid compared with the original version has a FP rate that is reduced from 40.0 to 22.2%, the false-negative (FN) rate remains at 0.0%, and the accuracy improved from 80.3% to 89.2%.

Conclusion

A comparison to OECD-adopted tests demonstrates that the further optimized OS test, like the original method, has a higher accuracy and lower FN rate for the detection of ‘nonirritants’ versus ‘irritants’ (GHS Category NC versus 2B/A and 1) than the other eye irritation tests (BCOP, EpiOcularTM Eye Irritation Test, ICE, Ocular Irritection®, and STE).

Disclosure statement

Lebrun Labs LLC and Stewart Lebrun, Ph.D., developed the OptiSafe test, sell the OptiSafe test as a kit, and provide testing services for the OptiSafe test. The patent, Biochemistry Based Ocular Toxicity Assay, Publication number: 20160290982, that covers the OptiSafe test and patent application, Methods and Reagents to Improve the Specificity, Sensitivity and Accuracy of Nonanimal Eye Safety Tests and patent application number 63048112, that covers the use of antioxidants including the use of ascorbic acid for improving nonanimal eye irritation tests are owned by Stewart Lebrun and Lebrun Labs LLC. Research was supported by the NIEHS of the National Institutes of Health under Award Numbers R43ES031881 and SB1ES031881. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional information

Funding

Research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health (NIEHS) Small Business Innovative Research (SBIR) Grant under Award Numbers R44ES025501 and SB1ES025501. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.